Health economic considerations in the management of type 2 diabetes.

Managed care interface

Volumn 15, Issue 1, 2002, Pages 66-71

  Clouse, Jon C ^a   Zitter, Mark ^a   Herman, Mary E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

BLOOD; CHRONIC DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE MANAGEMENT; ECONOMICS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

BLOOD GLUCOSE; CHRONIC DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 0036357549     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)